ArticleEuropean journal of neurology2026
Comorbidities for Predicting Progression Independent of Relapse Activity in Multiple Sclerosis Treated With B-Cell Depletion.
Article in European journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundProgression independent of relapse activity (PIRA) has been shown to account for a majority of the disability accumulation in relapsing-remitting multiple sclerosis (RRMS) patients treated with disease-modifying therapies. While comorbidities are common in MS and linked to disability progression, their role in PIRA remains unclear. We investigated whether comorbidities at treatment initiation could predict PIRA in RRMS patients receiving B-cell depleting therapy.
methodsThis population-based cohort study included RRMS patients initiating rituximab between August 2010 and April 2019, without relapses during six-year follow-up. PIRA was defined as confirmed disability worsening (Expanded Disability Status Scale). We performed hypothesis-driven analysis of pre-specified comorbidities and data-driven analysis of all ICD-10 codes from secondary care. Comorbidity-PIRA associations were assessed using adjusted logistic regression. Predictive performance for elastic net, random forest, XGBoost, and neural networks was evaluated as the area under the curve (AUC) and Brier score through nested cross-validation.
resultsAmong 2837 patients, 563 (20%) experienced PIRA within 6 years. The most prevalent comorbidities were depression/anxiety (36%), hypertension (15%), and headache (8%). No pre-specified comorbidities were statistically significant predictors of PIRA. Among all diagnosis codes, only neuromuscular bladder dysfunction reached significance after multiple comparison correction. Predictive models demonstrated modest performance (AUC 0.563-0.652) and adding comorbidities did not improve prediction.
conclusionsIn this rituximab-treated RRMS cohort, comorbidities at therapy start were not associated with higher PIRA risk when accounting for MS-associated disability. The association with bladder dysfunction likely reflects spinal tract engagement rather than an independent comorbidity effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.